Videau Manon, Thibault Maxime, Lebel Denis, Atkinson Suzanne, Bussières Jean-François
est candidate au Pharm. D. à l'Université Claude Bernard Lyon 1, Lyon, France, et assistante de recherche clinique, Unité de recherche en pratique pharmaceutique, Centre hospitalier universitaire Sainte-Justine, Montréal (Québec), B. Pharm., M. Sc., est pharmacien responsable des systèmes d'information, Département de pharmacie et Unité de recherche en pratique pharmaceutique, Centre hospitalier universitaire Sainte-Justine, Montréal (Québec), B. Pharm., M. Sc., FCSHP, est chef-adjoint aux soins pharmaceutiques, enseignement et recherche, Département de pharmacie et Unité de recherche en pratique pharmaceutique, Centre hospitalier universitaire Sainte-Justine, Montréal (Québec), B. Pharm., M. Sc., est chef-adjointe aux services pharmaceutiques, Département de pharmacie et Unité de recherche en pratique pharmaceutique, Centre hospitalier universitaire Sainte-Justine, Montréal (Québec), B. Pharm., M. Sc., MBA, FCSHP, FOPQ, est chef de Département de pharmacie et Unité de recherche en pratique pharmaceutique, Centre hospitalier universitaire Sainte-Justine, et professeur titulaire de clinique, Faculté de pharmacie, Université de Montréal, Montréal (Québec).
Can J Hosp Pharm. 2020 Mar-Apr;73(2):116-124. Epub 2020 Apr 1.
The use of controlled substances, especially opioids, is a public health concern. Canada is the country with the second greatest opioid use in the world. The use of these substances is associated with problems of misuse, as evidenced by North America's opioid crisis.
To describe and analyze usage patterns for controlled substances in a health care facility from 2003/04 to 2017/18, and to propose a tool for monitoring the use of controlled substances in this setting.
In this retrospective descriptive study, usage data for all controlled substances were extracted from the institution's supply management software for the period April 1, 2003, to March 31, 2018. The data are presented according to the classification in terms of number of Defined Daily Doses (DDD) per 1000 inpatient-days, using the DDD values proposed by the World Health Organization. Only descriptive statistics were determined.
During the last 15 years, use of controlled substances at the study facility dropped by 43% (min. 739 and max. 1292 DDD/1000 inpatient-days per year). From 2003/04 to 2017/18, the main therapeutic classes consumed (in decreasing order) were opioids, hypnotics and sedatives, anxiolytics, and general anesthetics. The main opioid molecules consumed in 2017/18 were hydromorphone and injectable morphine.
This retrospective descriptive study showed a decrease in the consumption of controlled substances in the study facility from 2003/04 to 2017/18. It also demonstrated the feasibility of developing a tool for monitoring the use of controlled substances in a health care facility. This approach could be implemented at a larger scale to foster comparisons between facilities.
管制药品的使用,尤其是阿片类药物,是一个公共卫生问题。加拿大是世界上阿片类药物使用量第二大的国家。这些药物的使用与滥用问题相关,北美阿片类药物危机就是明证。
描述并分析2003/04年至2017/18年期间一家医疗机构内管制药品的使用模式,并提出一种在此环境下监测管制药品使用的工具。
在这项回顾性描述性研究中,所有管制药品的使用数据均从该机构2003年4月1日至2018年3月31日期间的供应管理软件中提取。数据按照世界卫生组织提议的限定日剂量(DDD)值,以每1000住院日的DDD数量进行分类呈现。仅进行了描述性统计。
在过去15年中,研究机构的管制药品使用量下降了43%(每年最低739 DDD/1000住院日,最高1292 DDD/1000住院日)。从2003/04年到2017/18年,消耗的主要治疗类别(按降序排列)为阿片类药物、催眠药和镇静剂、抗焦虑药以及全身麻醉药。2017/18年消耗的主要阿片类药物分子为氢吗啡酮和注射用吗啡。
这项回顾性描述性研究表明,2003/04年至2017/18年期间研究机构内管制药品的消耗量有所下降。它还证明了开发一种医疗机构管制药品使用监测工具的可行性。这种方法可在更大范围内实施,以促进不同机构之间的比较。